Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;102(4):319-26.
doi: 10.5935/abc.20140033. Epub 2014 Feb 17.

Use of evidence-based interventions in acute coronary syndrome - Subanalysis of the ACCEPT registry

[Article in English, Portuguese]
Ricardo Wang  1 , Fernando Carvalho Neuenschwander  1 , Augusto Lima Filho  1 , Celsa Maria Moreira  1 , Elizabete Silva dos Santos  2 , Helder Jose Lima Reis  3 , Edson Renato Romano  4 , Luiz Alberto Piva e Mattos  5 , Otávio Berwanger  4 , Jadelson Pinheiro de Andrade  6
Affiliations

Use of evidence-based interventions in acute coronary syndrome - Subanalysis of the ACCEPT registry

[Article in English, Portuguese]
Ricardo Wang et al. Arq Bras Cardiol. 2014 Apr.

Abstract

Background: The recommendations in guidelines are based on evidence; however, there is a gap between recommendations and clinical practice.

Objective: To describe the practice of prescribing evidence-based treatments for patients with acute coronary syndrome in Brazil.

Methods: This study carried out a subanalysis of the ACCEPT registry, assessing epidemiological data and the prescription rate of acetylsalicylic acid, p2y12 inhibitors, antithrombotic drugs, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (IAT1RB), and statins. In addition, the quality of myocardial reperfusion in ST-segment elevation myocardial infarction was evaluated.

Results: This study assessed 2,453 patients. The prescription rates of acetylsalicylic acid, p2y12 inhibitors, antithrombotic drugs, beta-blockers, angiotensin-converting enzyme inhibitors/IAT1RB, and statins were as follows: in 24 hours - 97.6%, 89.5%, 89.1%, 80.2%, 67.9% and 90.6%; and at six months - 89.3%, 53.6%, 0%, 74.4%, 57.6% and 85.4%, respectively. Regarding ST-segment elevation myocardial infarction, only 35.9% and 25.3% of the patients underwent primary angioplasty and thrombolysis, respectively, within the recommended times.

Conclusion: This registry showed high initial prescription rates of antiplatelet drugs, antithrombotic drugs, and statins, and lower prescription rates of beta-blockers and angiotensin-converting enzyme inhibitors/IAT1RB. Independently of the class, the use of all drugs decreased by six months. Most patients with ST-segment elevation myocardial infarction did not undergo myocardial reperfusion within the time recommended.

PubMed Disclaimer

Conflict of interest statement

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1
Drug prescription rates in acute coronary syndrome within the first 24 hours, on hospital discharge, and at 6 months. § Except ASA; * significant reduction (p < 0.05) at all three specified times; † significant reduction only at 6 months; ‡ significant increase on hospital discharge compared to the first 24 hours and significant reduction at 6 months. ASA: acetylsalicylic acid; BB: beta-blocker; ACEI: angiotensin-converting enzyme inhibitor; AC: anticoagulants; APT: antiplatelet drug (p2y12 inhibitor).
Figure 2
Figure 2
Drug prescription rates in acute coronary syndrome according to the clinical findings (unstable angina, NSTEMI and STEMI) on patient’s admission (24 hours). † Except ASA; * p < 0.05. ASA: acetylsalicylic acid; BB: beta-blocker; ACEI: angiotensin-converting enzyme inhibitor; AC: anticoagulants; APT: antiplatelet drug (p2y12 inhibitor); NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction.
Figure 3
Figure 3
Drug prescription rates in acute coronary syndrome according to the clinical findings (unstable angina, NSTEMI and STEMI) on hospital discharge. † Except ASA; * p<0.05. ASA: acetylsalicylic acid; BB: beta-blocker; ACEI: angiotensin-converting enzyme inhibitor; AC: anticoagulants; APT: antiplatelet drug (p2y12 inhibitor); NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction.
Figure 4
Figure 4
Drug prescription rates in acute coronary syndrome according to the presence or absence of a cardiologist on duty on patient’s admission. ASA: acetylsalicylic acid; BB: beta-blocker; ACEI: angiotensin-converting enzyme inhibitor.
Figure 5
Figure 5
Patients admitted with ST-segment elevation acute myocardial infarction, who met the requirements for myocardial reperfusion. pt: patients; min: minutes.
See this image and copyright information in PMC

References

    1. Andrade JP, Piva e Mattos LA, Carvalho AC, Machado CA, Oliveira GM. National physician qualification program in cardiovascular disease prevention and integral care. Arq Bras Cardiol. 2013;100(3):203–211. - PubMed
    1. Nicolau JC, Franken M, Lotufo PA, Carvalho AC, Marin JA, Neto, Lima FG, et al. Utilização de terapêuticas comprovadamente úteis no tratamento da coronariopatia aguda: comparação entre diferentes regiões brasileiras. Análise do registro brasileiro de síndromes coronarianas agudas (BRACE - Brazilian Registry on Acute Coronary Syndromes) . Arq Bras Cardiol. 2012;98(4):282–289.
    1. Piegas LS, Avezum A, Guimaraes HP, Muniz AJ, Reis HJ, dos Santos ES, et al. Acute coronary syndrome behavior: results of a brazilian registry. Arq Bras Cardiol. 2013;100(6):502–510. - PubMed
    1. Berwanger O, Piva e Mattos LA, Martin JF, Lopes RD, Figueiredo EL, Magnoni D, et al. Evidence-based therapy prescription in high-cardiovascular risk patients: the react study. Arq Bras Cardiol. 2013;100(3):212–220. - PubMed
    1. Piegas LS, Feitosa G, Mattos LA, Nicolau JC, Rossi JM, Neto, Timerman A, et al. Sociedade Brasileira de Cardiologia Diretriz da Sociedade Brasileira de Cardiologia sobre tratamento do infarto agudo do miocárdio com supradesnível do segmento ST. Arq Bras Cardiol. 2009;93(6) supl.2:e179–e264. - PubMed

Publication types

MeSH terms

Substances